World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
48
Citations
10873
World Ranking
6135
National Ranking
2681

Best Publications

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

    Abhinay D. Joshi;Michael J. Pontecorvo;Chrisopher M. Clark;Alan P. Carpenter

  • A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

    Unknown

  • Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

    Michael J. Pontecorvo;Michael D. Devous;Michael Navitsky;Ming Lu

  • Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study

    R. N. Alcalay;E. Caccappolo;H. Mejia-Santana;M. X. Tang

  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study

    P. Murali Doraiswamy;Reisa A. Sperling;R. Edward Coleman;Keith A. Johnson

  • Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

    Andrew Siderowf;Danna Jennings;Shirley Eberly;David Oakes

  • [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy

    Andrea Varrone;Kenneth L. Marek;Danna Jennings;Robert B. Innis;Robert B. Innis

  • (123I) β-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome: Unmasking an Early Diagnosis

    Danna L. Jennings;John P. Seibyl;David Oakes;Shirley Eberly

  • Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders

    B. A. Racette;S. D. Tabbal;D. Jennings;L. Good

  • Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

    Danna Jennings;Andrew Siderowf;Matthew Stern;John Seibyl

  • Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

    Danna Jennings;Andrew Siderowf;Matthew Stern;John Seibyl

  • CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

    Ju-Hee Kang;Ju-Hee Kang;Brit Mollenhauer;Christopher S. Coffey;Jon B. Toledo

  • Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

    Tanya Simuni;Andrew Siderowf;Shirley Lasch;Chris S. Coffey

  • Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

    Kenneth Marek;John Seibyl;Shirley Eberly;David Oakes

  • Frequency of Known Mutations in Early-Onset Parkinson Disease: Implication for Genetic Counseling: The Consortium on Risk for Early Onset Parkinson Disease Study

    Roy N. Alcalay;Elise Caccappolo;Helen Mejia-Santana;Ming Xin Tang

  • Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury

    E M Mitsis;S Riggio;L Kostakoglu;D L Dickstein

  • Plasma apolipoprotein A1 as a biomarker for Parkinson disease

    Judy K. Qiang;Yvette C. Wong;Andrew Siderowf;Howard I. Hurtig

  • In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease

    Lana M. Chahine;Thomas G. Beach;Michael C. Brumm;Charles H. Adler

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: